John Swaim, MD
Family Medicine · Rockville, INNPI 1760570774
Payments from drug & device makers
Across 143 payments — averaging $34.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$878
- GSK$672
- AbbVie$503
- Otsuka America Pharmaceutical, Inc.$436
- AstraZeneca$372
- Lilly USA, LLC$273
- plus $2K from 22 others
What the payments were for
- Food & beverage$4,84899%
- Education$511%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 15 | $878 |
| GSK | 23 | $672 |
| AbbVie | 27 | $503 |
| Otsuka America Pharmaceutical, Inc. | 7 | $436 |
| AstraZeneca | 8 | $372 |
| Lilly USA, LLC | 7 | $273 |
| Pfizer | 7 | $254 |
| Lundbeck LLC | 12 | $203 |
| Amgen | 5 | $196 |
| Novartis | 4 | $147 |
| Radius Health, Inc. | 1 | $125 |
| Merck | 1 | $123 |
| Biohaven Pharmaceuticals, Inc. | 1 | $102 |
| Bayer | 2 | $98 |
| Johnson & Johnson | 1 | $91 |
| Mylan Specialty L.p. | 4 | $72 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $48 |
| E.r. Squibb & Sons, L.L.C. | 2 | $46 |
| Xeris Pharmaceuticals, Inc. | 2 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| Eisai Inc. | 2 | $35 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Sanofi-aventis U.S. LLC | 1 | $25 |
| Abbott | 1 | $21 |
| Supernus Pharmaceuticals, Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $19 |
| Masimo Corporation | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$349
- ABILIFY MAINTENA$236
- Ozempic$226
- Tymlos$125
- ELIQUIS$125
- VRAYLAR$125
- AREXVY$125
- SHINGRIX$123
- STEGLATRO$123
- TRELEGY ELLIPTA$121
- AIMOVIG$119
- MOUNJARO$104
- NURTEC ODT$102
- ENTRESTO$100
How this compares
$4,898 in reported general payments places this provider in the 85th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LeukeranChlorambucil | 11 | $152,789 |
| EliquisApixaban | 301 | $114,479 |
| XareltoRivaroxaban | 202 | $83,372 |
| JardianceEmpagliflozin | 118 | $79,340 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 72 | $61,830 |
| OzempicSemaglutide | 43 | $56,372 |
| MounjaroTirzepatide | 31 | $39,050 |
| VraylarCariprazine Hcl | 35 | $37,580 |
| Invega SustennaPaliperidone Palmitate | 11 | $28,986 |
| JanuviaSitagliptin Phosphate | 42 | $14,148 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 695 | $13,794 |
| NamzaricMemantine Hcl/Donepezil Hcl | 64 | $13,568 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $13,192 |
| EntrestoSacubitril/Valsartan | 41 | $12,941 |
| SymbicortBudesonide/Formoterol Fumarate | 28 | $10,574 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $254 | $114,479301 claims |
| Johnson & JohnsonXarelto, Invega Sustenna | $91 | $112,358213 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $672 | $69,13889 claims |
| Novo NordiskOzempic, Tresiba | $878 | $66,14670 claims |
| AbbVieVraylar, Namzaric | $503 | $51,14899 claims |
| Lilly USA, LLCMounjaro | $273 | $39,05031 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Brilinta | $372 | $30,12484 claims |
| MerckJanuvia | $123 | $14,14842 claims |
| NovartisEntresto | $147 | $12,94141 claims |
| Astellas Pharma US IncMyrbetriq | $19 | $3,85018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Rockville
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Steven SmithIndianapolis$2.5M
- Renee Michelle GalenNewburgh$2.1M
- Eric HewittAvon$1.7M
- Alexander Dela LlanaEvansville$1.6M
- Jonathan ConditMuncie$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.